Lesinurad is a uricosuric agent for the treatment of hyperuricemia associated with gout, which was found lacking in efficacy and safety. Here, scaffold hopping and molecular hybridization were exploited to modify all the structural components of lesinurad, and 36 novel compounds bearing bicyclic imidazolopyridine core were obtained. In a mouse model of acute hyperuricemia, 29 compounds demonstrated increased serum uric acid (SUA)-reducing activity; SUA was treated with <b>12</b>, <b>23</b>, and <b>29</b> about fourfold lower compared with that of lesinurad. Moreover, <b>23</b> exhibited stronger URAT1 inhibition activity (IC<sub>50</sub> = 1.36 μM) than lesinurad (IC<sub>50</sub> = 5.54 μM). Additionally, <b>23</b> showed favorable safety profiles, and no obvious acute toxicity was observed in Kunming mice under a single dose of 1000 mg·kg<sup>-1</sup>. <b>23</b> also achieved excellent pharmacokinetic properties with the oral bioavailability of 59.3%. Overall, all the results indicated that <b>23</b> is a promising drug candidate in the treatment of hyperuricemia and gout.